Successful Commercial Launch of Ryoncil® Highlighted at Global Healthcare Conferences Sep 14, 2025 09:18PM
Cantor Fitzgerald Reiterates Overweight Rating on Mesoblast Limited (MESO) Aug 29, 2025 06:55AM
Mesoblast and Oaktree Capital Enter Into Refinancing and Expansion of Senior Debt Facility Nov 21, 2021 07:31PM
Despite Concerns, Cantor Fitzgerald Thinks Mesoblast's (MESO) Ryoncil Could Be Approved Aug 11, 2020 08:19AM
Companies with NDRs 5/8 May 8, 2020 07:59AM


Feb 20, 2020 07:17AM Cantor Fitzgerald Reiterates Overweight Rating on Mesoblast Limited (MESO)
Oct 22, 2019 06:36AM Cantor Fitzgerald Assumes Mesoblast Limited (MESO) at Overweight
Jul 2, 2018 06:00AM Mesoblast Enters Into US$50M Financing with Novaquest Capital for Commercial Readiness of Remestemcel-l in the Treatment of Acute Graft Versus Host Disease
Mar 6, 2018 07:31PM Mesoblast Enters Into US$75 Million Non-Dilutive Credit Facility
Sep 25, 2017 07:27AM Mesoblast Presents Corporate Updates at Global Healthcare Conferences
Aug 30, 2017 06:19AM Mesoblast (MESO): Accelerated Approval Possible In 1Q18 - Cantor Fitzgerald
Jun 8, 2017 09:30AM Pre-Open Movers 06/08: (JWN) (BABA) (VSTM) Higher; (NLNK) (GEF) (MZOR) Lower (more...)
Jun 7, 2017 05:34PM After-Hours Stock Movers 06/07: (VSTM) (OKTA) (MESO) Higher; (GEF) (MSL) Lower (more...)
Jun 7, 2017 04:07PM Cantor Fitzgerald Starts Mesoblast Limited (MESO) at Overweight; 'Underappreciated Late-Stage Cell Therapies'